Do NOACs Improve Antithrombotic Therapy in Secondary @entity64 Prevention in Nonvalvular XXXX ?

@entity1 @entity64 @entity955 @entity1229 @entity385
UNASSIGNED: Guidelines recommended oral anticoagulant (OAC) for @entity385 @entity1 related to @entity955 ( @entity955 ). But, underprescription or underdose of @entity1229 was observed worldwide. We aimed to explore if the use of antithrombotic therapy in nonvalvular @entity955 (NVAF) @entity385 @entity1 improved after novel oral anticoagulants (NOACs) became available.Between January 2011 to December 2013, 360 acute @entity385 @entity1 related to NVAF were recruited. @entity1 were categorized into 2 groups based on the date (July 2012) of NOACs' availability. There were 184 @entity1 recruited before July 2012, and whereas 176 @entity1 after July 2012. Demographic data, interested factors, and the percentage of @entity1 on OAC were compared.One month after discharge, percentage of OAC utilization was significantly higher (29% versus 41%; P=0.022) as well as effective anticoagulation (22.2% versus 80.6%; P<0.001); @entity1229 utilization was significantly less (28.3% versus 11%; P<0.001) after NOACs became available. Antiplatelet agent utilization was high in 2 groups (57% versus 52%; P=0.36). Age (odd ratios [OR] 0.947; 95% confidence intervals [CI] 0.912-0.984; P=0.005), Barthel index (OR 1.012; 95% CI 1.000-1.025; P=0.05), and NOACs' availability (OR 1.857; 95% CI 1.086-3.175; P=0.024) were the significant factors affecting the use of OAC.A higher percentage of NVAF @entity385 @entity1 returning for their 1-month follow-up were treated with NOACs than with @entity1229 . The use of antithrombotic therapy improved after NOACs became available. But, the majority of the @entity1 were still received antiplatelet agent for @entity64 prevention.
